Nanjing Vazyme Biotech Co., Ltd. (688105.SS)
CNY 22.02
(4.61%)
CNY 22.02
(4.61%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 1.28 Billion CNY | -64.04% |
| 2022 | 3.56 Billion CNY | 90.99% |
| 2021 | 1.86 Billion CNY | 19.44% |
| 2020 | 1.56 Billion CNY | 482.92% |
| 2019 | 268.38 Million CNY | 57.13% |
| 2018 | 170.8 Million CNY | 52.0% |
| 2017 | 112.37 Million CNY | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q1 | 299.5 Million CNY | -28.25% |
| 2024 Q2 | 343.61 Million CNY | 14.73% |
| 2024 Q3 | 336.63 Million CNY | -2.03% |
| 2023 Q1 | 302.19 Million CNY | -76.09% |
| 2023 FY | 1.28 Billion CNY | -64.04% |
| 2023 Q4 | 417.43 Million CNY | 39.96% |
| 2023 Q3 | 298.25 Million CNY | 10.94% |
| 2023 Q2 | 268.84 Million CNY | -11.04% |
| 2022 Q3 | 685.29 Million CNY | 6.35% |
| 2022 Q2 | 644.37 Million CNY | -33.93% |
| 2022 Q1 | 975.33 Million CNY | 68.16% |
| 2022 FY | 3.56 Billion CNY | 90.99% |
| 2022 Q4 | 1.26 Billion CNY | 84.44% |
| 2021 Q3 | 463.06 Million CNY | 63.1% |
| 2021 Q1 | 541.64 Million CNY | 27.08% |
| 2021 Q2 | 283.92 Million CNY | -47.58% |
| 2021 FY | 1.86 Billion CNY | 19.44% |
| 2021 Q4 | 579.99 Million CNY | 25.25% |
| 2020 Q1 | 207.26 Million CNY | 0.0% |
| 2020 FY | 1.56 Billion CNY | 482.92% |
| 2020 Q3 | 344.79 Million CNY | -41.18% |
| 2020 Q2 | 586.19 Million CNY | 182.82% |
| 2020 Q4 | 426.2 Million CNY | 23.61% |
| 2019 FY | 268.38 Million CNY | 57.13% |
| 2018 FY | 170.8 Million CNY | 52.0% |
| 2017 FY | 112.37 Million CNY | 0.0% |